3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3,4-dihydro-1H-quinolin-2-one | 190203-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3,4-dihydro-1H-quinolin-2-one
• CAS: 190203-86-2
• 化学式: C₁₇H₂₇NO₂Si
• 分子量: 305.492
• InChiKey: LPQFBFRDVQUASR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.21
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  38.33
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3,4-dihydro-1H-quinolin-2-one 在 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 生成 3-(2-Hydroxy-ethyl)-1-methyl-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: discovery of mixed 5-HT1B/5-HT2A receptor antagonists

  摘要：

  Quinolin-2-ones bearing a heteroaryl-piperazine linked by a two carbon chain at the 3- or 4-position were synthesised and evaluated as mixed 5-HT1B/5-HT2A receptor antagonists. Potent mixed antagonists were obtained with thieno[3,2-c]pyridine derivatives. In this series, compound 2.1 (SL 65.0472) proved to be functional antagonist at both the 5-HT2A receptor (rat in vivo 5-HT-induced hypertension model) and the 5-HT1B receptor (dog in vitro saphenous vein assay). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00118-3
• 作为产物：
  描述：

  3-[(2-nitrophenyl)methylene]dihydrofuran-2(3H)-one 在 palladium on activated charcoal 咪唑 、 氢气 作用下， 以 四氢呋喃 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: discovery of mixed 5-HT1B/5-HT2A receptor antagonists

  摘要：

  Quinolin-2-ones bearing a heteroaryl-piperazine linked by a two carbon chain at the 3- or 4-position were synthesised and evaluated as mixed 5-HT1B/5-HT2A receptor antagonists. Potent mixed antagonists were obtained with thieno[3,2-c]pyridine derivatives. In this series, compound 2.1 (SL 65.0472) proved to be functional antagonist at both the 5-HT2A receptor (rat in vivo 5-HT-induced hypertension model) and the 5-HT1B receptor (dog in vitro saphenous vein assay). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00118-3